Physician profile
Sam Diasti
NPI 1730175944
$5,449.31
in general payments reported to CMS, 2019-2025
50 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $283 · 2021: $282 · 2022: $454 · 2023: $614 · 2024: $919 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $862.21 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $628.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $326.58 | 2019-2024 | Qulipta, Ubrelvy |
| Pfizer INC. | $320.25 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $320.17 | 2019-2023 | Spravato |
| Glaxosmithkline, LLC. | $233.18 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $226.21 | 2019-2025 | Evenity, Repatha, Krystexxa |
| Lilly USA, LLC | $210.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.19 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $156.89 | 2019 | |
| Sanofi-Aventis U.S. LLC | $152.92 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.51 | 2024 | Jardiance |
| Medtronic Vascular, INC. | $137.68 | 2019 | |
| Exact Sciences Corporation | $130.13 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $114.75 | 2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Diasti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.